← Leaderboards
Mengqian Chen
Senex Biotechnology, Inc.
$1,097,431
Attributed
$3,386,611
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,386,611 · 4
By mechanism
R44$1,977,275 · 1
R01$609,336 · 1
R41$400,000 · 1
R43$400,000 · 1
Top collaborators
- Eugenia V Broude2 shared
- Michael B Lilly2 shared
- Igor B Roninson2 shared
- Yusuke Shiozawa2 shared
- Hexin Chen1 shared
- Mythreye Karthikeyan1 shared
Others in their field
Other Emerging Leaders on “Prevent”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$141,293,697
- Kimberly Smith · Ppd Development Lp$115,671,664
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$112,282,390
- Beth Baseler · Leidos Biomedical Research, Inc.$100,071,064
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
Research focus
PreventTumorProgramsPhosphotransferasesGrowthTranscriptomicsGene ExpressionGenetic TranscriptionResistancePharmaceutical PreparationsTumor XenograftIn VivoMalignant NeoplasmsTumor GrowthNeoplasm MetastasisStromal CellsDrug CandidateToxic EffectPathway InteractionsCell LineClinical TrialsTranscriptional ReprogrammingAntineoplastic AgentsClinic
Grant awards (5)
Preventing adaptive drug resistance through Mediator kinase inhibition$609,336
R01 · FY2025 · CA · contact PI
Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer$400,000
R41 · FY2025 · CA · contact PI
Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition$400,000
R43 · FY2022 · CA · contact PI
CDK8/19 inhibitors for therapy of advanced prostate cancer$846,340
R44 · FY2021 · CA · contact PI
CDK8/19 inhibitors for therapy of advanced prostate cancer$1,130,935
R44 · FY2020 · CA · contact PI